| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_7a438573e256d793720ecf1102ae5693
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0dc627065da07a4949159f716c9919bd |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D403-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-02 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4178
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-02 |
| filingDate |
2018-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_249601ce22aa914ae2991099ac751705
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_754382ed021a5303bc8c01c9dfa99450
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_51ba5be62bdbd15f8ce99a602cf00183 |
| publicationDate |
2018-12-16-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
TW-201842906-A |
| titleOfInvention |
Method for treating patients with hematological malignancies |
| abstract |
The invention includes administering a 2,3-dihydro-isoindol-1-one compound or a pharmaceutically acceptable salt, ester, solvate and / or prodrug thereof for the treatment of a hematological cancer such as acute myeloid leukemia ( AML). The invention further relates to reducing or inhibiting cell proliferation activated by wild-type or mutant Fms-like tyrosine kinase-3 receptor (FLT3). The invention further relates to methods for inhibiting or reducing abnormal (eg, over-expressed) wild-type or mutant BTK activity or performance in a subject in need. |
| priorityDate |
2017-02-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |